Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

(NASDAQ:ABP), BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. […]

Metapack(R) Positioned as a Leader in the SPARK Matrix(TM): Multi-Carrier Parcel Management Solutions (MCPMS), Q4 2025 by QKS Group

Pune, India, Jan. 15, 2026 (GLOBE NEWSWIRE) — The QKS Group SPARK Matrix(TM) provides competitive analysis & ranking of the leading MCPMS vendors. Metapack, a leading delivery platform, has received strong ratings across technology excellence and customer impact. QKS Group announced today that it has named Metapack as a leader in the SPARK Matrix(TM): Multi-Carrier

Talen Energy Continues Portfolio Expansion with Acquisition of Additional High-Quality PJM Natural Gas Assets from Energy Capital Partners

(NASDAQ:TLN),(LSE:BPT.L), HOUSTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen,” “we,” or “our”) (NASDAQ: TLN), a leading independent power producer, announced it has signed definitive agreements to add approximately 2.6 gigawatts of natural gas generation capacity to Talen's portfolio through the acquisition of the Waterford Energy Center (“Waterford”) and Darby Generating Station (“Darby”)

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

(NasdaqGM:AXSM), NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia. FORWARD (Fibromyalgia Response

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa

LONDON and MILAN, Jan. 15, 2026 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1, their Phase 1/2 first-in-human clinical trial evaluating AAVB-081 for the treatment of retinitis pigmentosa associated with Usher syndrome type 1B (USH1B). LUCE-1 is a

Verano Announces Agreement to Upsize Revolving Credit Facility Commitment to $100,000,000 and Extend Maturity Date

(Neo:VRNO.NE),(OTC US:VRNO),(OtherOTC:VRNO), Amendment adds incremental $25,000,000 and extends maturity date from September 29, 2028 to February 28, 2029 CHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced an amendment to its existing $75,000,000 revolving credit facility agented by

Sable Announces Option Agreement Consolidating the New “Zorro” Project in San Juan, Argentina

(TSX-V:SAE),(OTC US:SBLRF),(Other OTC:SBLRF), VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV:SAE | OTCQB:SBLRF) is pleased to announce that it has entered into a binding letter agreement with an arm's length party, with the intent to enter into a definitive option agreement to acquire a 100% interest

The Miller Group – Miller Capital Voted Best Investment Firm 2026 Seventh Consecutive Year

SCOTTSDALE, Ariz., Jan. 15, 2026 (GLOBE NEWSWIRE) — Out of twenty firms that were nominated, The Miller Group – Miller Capital is extremely pleased to be voted Arizona Foothills Magazine's “Best of Our Valley” – Best Investment Firm for the eighth time, including 2013. Miller Capital also earned a top two position in 2019, 2018,

Mercury Awarded Contracts for U.S. Space and Strategic Weapons Programs

(NASDAQ:MRCY), ANDOVER, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, today announced contract awards totaling more than $60 million for work associated with two critical U.S. space and strategic weapons programs. In December, Mercury was awarded a development contract

VapeAway(R) LLC Announces First Patient Enrolled in Clinical Study of Novel Vaping Cessation Device

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) — VapeAway(R) LLC, a healthcare company focused on developing innovative solutions for nicotine dependence due to vaping, today announced that the first patient has been enrolled in its clinical study evaluating its patented VapeAway(R) filter (technology) and fix bar (Fix+Bar) device system, a non-pharmacologic (“drug-free”) device designed to

Scroll to Top